We are very grateful to the following corporate partners for all they do to support our work and our community.
Sepul Bio is a business unit within Thea exclusively focused on developing treatments for inherited retinal diseases. Sepul Bio’s initial focus will be to develop two flagship assets: Sepofarsen and Ultevursen. Sepofarsen is an investigational RNA therapy targeting Leber congenital amaurosis 10. This therapy is designed to address vision problems by addressing the underlying genetic mutation. Sepofarsen aims to skip aberrant mutation in the mRNA, leading to the production of functional protein. Ultevursen, also based on RNA technology, is aimed at addressing vision loss in Usher syndrome type 2a and non-syndromic retinitis pigmentosa.
Janssen Pharmaceuticals, one of the Pharmaceutical Companies of Johnson & Johnson, has established a new focus on Retinal Diseases to develop transformational therapies and platforms that restore and preserve vision.
Abbvie a pharmaceutical and research development company.
AAvantgarde, a biotechnology company working on developing treatments for Usher syndrome type 1B and Stargardt disease.
We’d love to hear from you if you are interested in working with us. We take a flexible and personalised approach to our relationships with corporate supporters – give our friendly fundraising team a call on 01280 815900 or email fundraising@RetinaUK.org.uk for an informal chat.
"I have worked closely with Retina UK for over five years. I have always found the team to be professional, fast responding, and informed."Andy Bolan, Sepul Bio.